Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT01682213, this PHASE2 trial focuses on Melanoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Jun 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jul 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- National Comprehensive Cancer Network
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .